WuXi AppTec Research Service Division and Cyclica Collaborate to Drive Polypharmacology in Drug Discovery Through AI-Augmented Technologies
TORONTO, ON, CANADA (August 16, 2018) – WuXi AppTec Research Service Division (www.wuxiapptec.com), and Cyclica (www.cyclicarx.com) are pleased to announce a multi-phase collaboration to advance drug discovery programs by driving insights into small molecule polypharmacology, while further evolving Cyclica’s biophysics and AI-augmented platform. Through a multi-phase collaboration, WuXi will leverage and evaluate Cyclica’s cloud-based proteome […]
Cyclica Announces Ligand Express Academic Polypharmacology (LEAP) Program under Cyclica Academic Partnership Program (CAPP)
TORONTO, ON, CANADA (August 1, 2018) – Cyclica Inc. is pleased to announce the inaugural Ligand Express Academic Polypharmacology (LEAP) Program under the Cyclica Academic Partnership Program (CAPP). Cyclica recently launched its official academic partnership program – CAPP – whereby Cyclica will be supporting revolutionary research with its Drug Discovery Program. LEAP is the first […]
Cyclica Announces the Appointment of Dr. Mostafa Analoui as Chairman of the Board of Directors
TORONTO, ON, CANADA (Jul 10, 2018) – Cyclica Inc. is pleased to announce the appointment of Dr. Mostafa Analoui, Ph.D. as Chairman of its Board of Directors (BoD). Dr. Analoui has been a member of the BoD since October 2016, and has brought to Cyclica deep expertise in the pharmaceutical industry, and in venture capital […]
Cyclica and Translatum Medicus inc (TMi) Announce Partnership to Advance Small Molecule Discovery for Age-Related Macular Degeneration
TORONTO, ON, CANADA (January 8, 2018) – Cyclica Inc (www.cyclicarx.com) and Translatum Medicus Inc (TMi, www.translatummedicus.com), both resident companies at Johnson & Johnson Innovation, JLABS @ Toronto, located in the MaRS Centre, Toronto, Canada, are pleased to announce a partnership to advance the discovery of small molecule treatments for blinding eye disease, first focusing on “dry” age-related macular degeneration […]
Cyclica Launches Ligand Express™, a Disruptive Cloud-Based Platform to Revolutionize Drug Discovery
TORONTO, ON, CANADA (November 30, 2017) – Cyclica is launching its novel cloud-based, proteome screening platform, Ligand Express™. The unique platform, which harnesses biophysics, biological data, and artificial intelligence (AI), is actively being used by pharmaceutical scientists to more efficiently navigate the drug discovery pipeline. The web-accessible platform (www.ligandexpress.com) grants users access to Cyclica’s AI-assisted, […]
Cyclica Announces the Addition of Issi Rozen to its Scientific Advisory Board (SAB)
TORONTO, ON, CANADA (October 23, 2017) – Cyclica Inc. is pleased to announce that Issi Rozen has joined its Scientific Advisory Board. Issi is the Chief Business Officer at the Broad Institute of MIT and Harvard, where he is responsible for partnering with the life sciences industry and venture investors, and developing innovative scientific and business […]
Toronto Start-Up, Cyclica, Introduces Big Data Technology for Personalized Healthcare
Press release adapted from an article hosted by SOSCIP (original article here). TORONTO, CA, CANADA (September 20, 2017). A Toronto-based start-up is accessing the SOSCIP cloud analytics platform to develop a technology that will offer insight into how different people respond to therapeutic drugs at a genetic level. Cyclica is an early-stage computational biotechnology company that over the […]
Cyclica Announces Residency in Johnson & Johnson Innovation, JLABS @ Toronto
TORONTO, ON, CANADA (September 11, 2017) – Cyclica Inc. (www.cyclicarx.com), a Toronto-based life sciences technology company, is pleased to announce it is now a resident company at Johnson & Johnson Innovation, JLABS @ Toronto, located in the MaRS Centre in Toronto, Canada. JLABS @ Toronto is a 40,000 square-foot life science innovation center. The labs provide […]
Cyclica Announces the Addition of Dr. Shane Climie as Vice President of Corporate Development
TORONTO, ON, CANADA (September 6, 2017)- Cyclica Inc. is pleased to announce that it has added Dr. Shane Climie as Vice President of Corporate Development. Shane has more than 25 years of R&D and business development experience in the life sciences and pharmaceutical industry. He has led research teams involved in all aspects of drug discovery […]
Cyclica collaborates with Dr. Linda Penn of the at UHN to Elucidate the Mechanism of Action of a Synergistic Drug pair for the treatment of Cancer
Toronto, ON, Canada (August 2, 2017) – Dr. Linda Penn’s lab at Princess Margaret Cancer Centre and Cyclica Inc., both located in Toronto, Canada, will collaborate on a special project utilizing the Ligand Express™ drug discovery informatics platform. Dr. Penn’s group specializes in molecular oncology (Dr. Penn holds a Canada Research Chair Tier 1 appointment), with a focus on […]